N/A
Manufactured by Novo Nordisk
24,125 FDA adverse event reports analyzed
Last updated: 2026-04-14
HUMAN INSULIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Novo Nordisk. The most commonly reported adverse reactions for HUMAN INSULIN include BLOOD GLUCOSE INCREASED, BLOOD GLUCOSE DECREASED, NAUSEA, DRUG INEFFECTIVE, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for HUMAN INSULIN.
Out of 12,254 classified reports for HUMAN INSULIN:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 24,125 FDA FAERS reports that mention HUMAN INSULIN. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include BLOOD GLUCOSE INCREASED, BLOOD GLUCOSE DECREASED, NAUSEA, DRUG INEFFECTIVE, DIARRHOEA, DYSPNOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Novo Nordisk in connection with HUMAN INSULIN. Always verify the specific product and NDC with your pharmacist.